Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + mitomycin-c
- Development stage
- Unknown
- Lead developer
- Yakult Honsha
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of irinotecan (CPT-11), a topoisomerase I inhibitor, and mitomycin-C (MMC), an alkylating agent. This combination has been studied primarily for advanced gastric cancer and colorectal cancer, showing synergistic antitumor effects in preclinical studies. The recommended dosing is typically irinotecan 150 mg/m² plus MMC 5 mg/m² administered every two weeks.
- Brand names
- Camptosar (for irinotecan)Mutamycin (for mitomycin C)
- Other names
- irinotecan + mitomycin-cCPT-11 + MMC
02
Targets
TOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on irinotecan + mitomycin-c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + mitomycin-c.